GenSight Biologics S.A. (FRA:G49N)
Germany
· Delayed Price · Currency is EUR 0.111
-0.016 (-12.74%)
At close: Dec 4, 2025
GenSight Biologics Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | -15.12 | -14 | -26.22 | -27.63 | -28.62 | -34.02 | Upgrade
|
| Depreciation & Amortization | 0.66 | 1.06 | 2.18 | 1.06 | 0.93 | 0.93 | Upgrade
|
| Stock-Based Compensation | 0.6 | 0.78 | 0.59 | -3.36 | 4.83 | 3.46 | Upgrade
|
| Other Operating Activities | -0.04 | -1.65 | -3.66 | 0.09 | 0.88 | 9.02 | Upgrade
|
| Change in Accounts Receivable | 0.03 | - | -0 | 0.76 | -0.7 | 0.79 | Upgrade
|
| Change in Accounts Payable | 3.55 | 0.16 | -2.23 | -2.15 | 2.4 | 0.34 | Upgrade
|
| Change in Other Net Operating Assets | 2.26 | 0.72 | 4.69 | -2.52 | 3.14 | 4.43 | Upgrade
|
| Operating Cash Flow | -8.05 | -12.94 | -24.66 | -33.75 | -17.14 | -15.04 | Upgrade
|
| Capital Expenditures | - | -0 | -0.01 | -0.25 | -0.03 | -0.01 | Upgrade
|
| Investment in Securities | -0.05 | 0.02 | 0.22 | 0.42 | 0.02 | - | Upgrade
|
| Other Investing Activities | -0 | -0 | - | - | - | -0.37 | Upgrade
|
| Investing Cash Flow | -0.05 | 0.02 | 0.21 | 0.17 | -0.02 | -0.38 | Upgrade
|
| Long-Term Debt Issued | - | - | 14.18 | 10.8 | - | 11.71 | Upgrade
|
| Long-Term Debt Repaid | - | -2.9 | -1.87 | -8.68 | -3.65 | -0.71 | Upgrade
|
| Net Debt Issued (Repaid) | -2.84 | -2.9 | 12.31 | 2.12 | -3.65 | 11 | Upgrade
|
| Issuance of Common Stock | 3.93 | 14 | 3.96 | 0 | 30 | 25.38 | Upgrade
|
| Repurchase of Common Stock | -0.01 | -0.03 | -0.1 | -0.19 | -0.31 | - | Upgrade
|
| Other Financing Activities | 0.64 | 2.47 | -0.31 | -1.83 | -2.3 | -2.52 | Upgrade
|
| Financing Cash Flow | 1.72 | 13.54 | 15.86 | 0.1 | 23.74 | 33.86 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.29 | -0.29 | 0.12 | -0.19 | -0.24 | 0.25 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -0 | - | - | - | -0 | - | Upgrade
|
| Net Cash Flow | -6.67 | 0.33 | -8.48 | -33.68 | 6.35 | 18.69 | Upgrade
|
| Free Cash Flow | -8.05 | -12.94 | -24.67 | -34.01 | -17.17 | -15.05 | Upgrade
|
| Free Cash Flow Margin | -851.96% | -492.88% | -832.42% | -698.97% | -222.74% | -202.28% | Upgrade
|
| Free Cash Flow Per Share | -0.07 | -0.14 | -0.51 | -0.73 | -0.38 | -0.43 | Upgrade
|
| Cash Interest Paid | 0.44 | 0.28 | 0.37 | 1.87 | 0.84 | 0.71 | Upgrade
|
| Levered Free Cash Flow | -3.2 | -6.69 | -14.13 | -29.49 | -13.79 | -6.46 | Upgrade
|
| Unlevered Free Cash Flow | -3.14 | -5.72 | -12.16 | -27.83 | -12.43 | -5.38 | Upgrade
|
| Change in Working Capital | 5.84 | 0.87 | 2.45 | -3.92 | 4.84 | 5.57 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.